Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fennec Pharmaceuticals Inc. - Common Stock (NQ:FENC)

8.760 +0.090 (+1.04%)
Streaming Delayed Price Updated: 9:59 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,879
Open 8.630
Bid (Size) 8.670 (1)
Ask (Size) 8.850 (1)
Prev. Close 8.670
Today's Range 8.415 - 8.760
52wk Range 3.960 - 9.420
Shares Outstanding 27,527,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fennec Q2 Sales Jump 33 Percent
Via The Motley Fool
Fennec (FENC) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings Intellectual Property

Performance

YTD
+39.3%
+39.3%
1 Month
+6.8%
+6.8%
3 Month
+7.2%
+7.2%
6 Month
+38.6%
+38.6%
1 Year
+68.5%
+68.5%

More News

Read More
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Reports Mixed Q2 2025 Earnings with Revenue Slight Miss and Wider-Than-Expected Loss
Via Chartmill
Earnings Scheduled For August 14, 2025
Via Benzinga
Fennec Pharmaceuticals Earnings Preview
Via Benzinga
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Via Benzinga
Topics Economy Stocks
Fennec Pharmaceuticals's Earnings Outlook
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Earnings Scheduled For March 10, 2025
Via Benzinga
Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Earnings Scheduled For November 6, 2023
Via Benzinga
Preview: Fennec Pharmaceuticals's Earnings
Via Benzinga
Analyst Ratings for Fennec Pharmaceuticals
Via Benzinga
Recap: Fennec Pharmaceuticals Q1 Earnings
Via Benzinga
3 Dirt-Cheap Stocks Under $10 That Could EXPLODE!
Via InvestorPlace
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Earnings Outlook For Fennec Pharmaceuticals
Via Benzinga
Analyst Ratings for Fennec Pharmaceuticals
Via Benzinga
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 21, 2024
Via Benzinga
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Highlighted for Surprising Price Action
Via Investor Brand Network
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Making Surprising Moves in Monday Session
Via Investor Brand Network
7 Biotech Stocks Sitting in the Sweet Spot
Via InvestorPlace

Frequently Asked Questions

Is Fennec Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, Fennec Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does Fennec Pharmaceuticals Inc. - Common Stock trade on?
Fennec Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Fennec Pharmaceuticals Inc. - Common Stock?
The ticker symbol for Fennec Pharmaceuticals Inc. - Common Stock is FENC on the Nasdaq Stock Market
What is the current price of Fennec Pharmaceuticals Inc. - Common Stock?
The current price of Fennec Pharmaceuticals Inc. - Common Stock is 8.760
When was Fennec Pharmaceuticals Inc. - Common Stock last traded?
The last trade of Fennec Pharmaceuticals Inc. - Common Stock was at 09/16/25 09:59 AM ET
What is the market capitalization of Fennec Pharmaceuticals Inc. - Common Stock?
The market capitalization of Fennec Pharmaceuticals Inc. - Common Stock is 241.14M
How many shares of Fennec Pharmaceuticals Inc. - Common Stock are outstanding?
Fennec Pharmaceuticals Inc. - Common Stock has 241M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.